ArticleNews reportPHN-05582026-11-02 03:50 CT

Ascletis Takes Aim at Weight-Loss Opportunity With Two-Pronged Approach; ASC48 and ASC37 Data to Debut in Washington in November

Source · finance.biggo.com

TLDR

Ascletis announced it will present preclinical findings on ASC48 and the peptide ASC37 at ObesityWeek 2026 in Washington, D.C., November 14–17. The company reports ASC37 had a half-life six times longer than retatrutide in non-human primates; human efficacy and safety remain unverified.

01—Key points

01ASC48 is an oral small-molecule GIPR agonist; ASC37 is a GLP-1R/GIPR/GCGR triple-target peptide.
02The company reports significant weight loss with ASC37 in diet-induced obese mice.
03Both presentations concern preclinical research, not human clinical results.

Why it matters Editorial

The findings concern Ascletis’s development of differentiated obesity therapies, but clinical trials are still needed to verify efficacy and safety in humans.

Read the original at finance.biggo.com↗

Summary generated with AI and reviewed by an editor. The original source governs; summaries can contain errors. Information only — not medical advice. Full disclaimer.